Medical Rx (cath) Time AdmissionCathDischarge No Cath Cath PCI Surgery Medical Rx (no cath) Medical Rx No disease (82 % of total) (18 % of total) (52%

Slides:



Advertisements
Similar presentations
Welcome to the EDICT for ACS Cardiovascular Forum.
Advertisements

Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino
Jointly Sponsored by the University of Massachusetts Medical School Office of Continuing Education and CMEducation Resources, LLC. Funded by an Independent.
Critical Challenges in Cardiovascular Medicine Advancing Management of Acute Coronary Syndromes(ACS)Establishing Interventional Cardiology & Emergency.
NAPLES Novel Approaches for Preventing or Limiting Event Study Randomised Comparison of Bivalirudin Monotherapy versus Unfractionated Heparin plus Tirofiban.
A ggrastat- Phase of the AGGRASTAT to ZOCOR (A to Z) Trial Comparison of the safety and efficacy of unfractionated heparin versus enoxaparin in combination.
Franz Weidinger 2. Medical Department (Cardiology) Hospital Rudolfstiftung Vienna, Austria SOLACI ´12, Mexico City, Interventional Pharmacology 2, Thursday.
NSTEMI Acute Coronary Syndromes
Rabih R. Azar, MD, MSc, FACC Director of Cardiovascular Research Hotel Dieu de France Hospital Associate Professor of Medicine Saint Joseph University.
Facilitated PCI & rescue PCI Dolly mathew. Primary PCI is the preferred reperfusion strategy in STEMI Most patients donot arrive at the PCI center within.
Decline in the Use of Drug-Eluting Stents for Patients With NSTEMI Undergoing PCI: Results From the CRUSADE and ACTION Registries Matthew T. Roe, Christopher.
What Have We Learned from the CRUSADE Registry
Stone p2203/Abstract/ Conclusions
PCI - A prospective, randomized, double- blind substudy of patients undergoing PCI in the CURE trial.
Timing of Intervention in Patients with Acute Coronary Syndromes (TIMACS) AHA, 2008.
Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.
Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
Clopidogrel in ACS: Overview Investigator, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Assistant Professor of Medicine, Harvard.
Importance and Impact of Bleeding on ACS Clinical Outcomes Sunil V. Rao MD Assistant Professor of Medicine Duke University Medical Center Durham VA Medical.
Why Bleeding Matters in ACS Importance of Multi-specialty ED and IC Therapeutic (EDICT) Alignment of Upstream Care for ACS Sunil Rao, MD, FACC Director.
Major Bleeding Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With ACS: Results From the ACUITY Trial Steven V. Manoukian,
BLEEDING AND ACUTE CORONARY SYNDROMES Cardiac Catherization Conference Syed Raza MD Cardiology Fellow VCU Medical Center 06/02/2011.
Sunil V. Rao MD The Duke Clinical Research Institute The Durham VA Medical Center Duke University Medical Center Transradial PCI in Octogenarians: Caveats,
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Applications of bivalirudin in interventional cardiology
TARGET and TACTICS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for.
Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial Presented at AHA Scientific Sessions Nov. 15, 2000.
New Horizons for Patients with ST-Elevation Myocardial Infarction Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation.
Clinical Trial Results. org Characteristics, Management, and Outcomes of 5,557 Patients Age ≥90 Years With Acute Coronary Syndromes: Results From the CRUSADE.
TACTICS- TIMI 18 Treat Angina with Aggrastat TM and Determine Cost of Therapy with an Invasive or Conservative Strategy.
Major Bleeding is Associated with Increased 30-Day Mortality and Ischemic Complications in Patients with Non-ST Elevation Acute Coronary Syndromes Undergoing.
The Leeds Teaching Hospitals NHS Trust PHARMACOLOGY IN ACS OVERVIEW OF THE DATA : PRACTICAL ADVICE JIM McLENACHAN, LEEDS. 25 th January, 2007.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Bivalirudin: Myths vs Reality? Dr Reman McDonagh Nycomed UK Ltd Conflict of Interest: Senior Manager working for Nycomed UK Ltd.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Eptifibatide plus Heparin Increases the Risk of Major and Minor Hemorrhagic Complications Compared to Bivalirudin in Patients with Normal Renal Function.
Gender Differences in Long-Term Outcomes Following PCI of Patients with Non-ST Elevation ACS: Results from the ACUITY Trial Alexandra J. Lansky on behalf.
Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy BMS & Sanofi Aventis Sponsored.
NICE-3 National Investigators Collaborating on Enoxaparin XXII nd Congress of the European Society of Cardiology August 30, 2000 Amsterdam, The Netherlands.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Impact Of Diabetes Mellitus On The Safety And Effectiveness Of Bivalirudin In Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty:
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.
1 Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial N Engl J Med 2001;344:
The American College of Cardiology Presented by Dr. Adnan Kastrati
MCV Campus Ginger Edwards.
Major Bleeding is Associated with Increased Short-Term Mortality and Ischemic Complications in Non-ST Elevation Acute Coronary Syndromes: The ACUITY Trial.
EARLY ACS Trial Rationale and Design
Antiplatelet Therapy For STEMI: The Case for Cangrelor
Transfusion is Associated with Increased 30-Day Mortality and Ischemic Complications in Non-ST Elevation Acute Coronary Syndromes: The ACUITY Trial Steven.
Seeking the Optimal Upstream Therapy for Patients with ACS: Fondaparinux- Low Bleeding Rate and Low Cost Sanjit S. Jolly MD, Interventional Cardiologist,
Preventing Thrombotic Complications in ACS: State of the Art
R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R
Terms of Use. Terms of Use.
Late Breaking Clinical Trials
Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:
Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.
% Heparin + GPI IIb/IIIa Bivalirudin +
The European Society of Cardiology Presented by RJ De Winter
An Analysis of the ACUITY Trial Lincoff AM, JACC Intv 2008;1:639–48
Importance and Impact of Bleeding on ACS Clinical Outcomes
Maintenance of Long-Term Clinical Benefit with
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
Baseline Characteristics
IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.
Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.
R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R
Presentation transcript:

Medical Rx (cath) Time AdmissionCathDischarge No Cath Cath PCI Surgery Medical Rx (no cath) Medical Rx No disease (82 % of total) (18 % of total) (52% of total, 63% of those undergoing cath) 40 % < 48 hrs 12 % > 48 hrs (12% of total, 15% of those undergoing cath) 63 % < 48 hrs 19 % > 48 hrs CRUSADE Registry 10/04-9/05 n=35,897 Patient X ACS Management Pathways Cath Medical Rx

SYNERGYLMWHESSENCE CUREClopidogrel Bleeding risk Ischemic risk GP IIb/IIIa blockers PRISM-PLUS PURSUIT ACUITY TACTICS TIMI-18 Early invasive PCI ~ 5% stents ~85% stents Drug-eluting stents ISAR-REACT 2 Milestones in ACS Management OASIS-5 [ Fondaparinux ] Anti-Thrombin Rx Anti-Platelet Rx Treatment Strategy Heparin Aspirin Conservative ICTUSBivalirudin REPLACE 2

Ischemic Complications Death MI Urgent TVR Death MI Urgent TVR Evolving Paradigm for Evaluating ACS Management Strategies Composite Adverse Event Endpoints

Ischemic Complications Hemorrhage HIT Death MI Urgent TVR Death MI Urgent TVR Major Bleeding Minor Bleeding Thrombocytopenia Major Bleeding Minor Bleeding Thrombocytopenia Composite Adverse Event Endpoints Evolving Paradigm for Evaluating ACS Management Strategies

Risk of events Risk of bleeding Thrombosis Hemostasis Two sides of the same coin Degree of Anticoagulation Risk Balancing Events and Bleeding

Death4.3% (Re)-Infarction2.5% CHF8.0% Cardiogenic Shock2.6% Stroke0.8% Non-CABG Transfusion9.9% Bhatt DL, et al. JAMA Nov 3;292(17): CRUSADE In-Hospital Outcomes

Quali sono i pazienti a rischio di sanguinamento? Bleeding in ACS Domanda:

Independent Predictors of Major Bleeding in Acute Coronary Syndromes Moscucci, GRACE Registry, Eur Heart J Oct;24(20): Predictors of Major Bleeding in ACS Older Age Older Age Female Gender Female Gender Renal Failure Renal Failure History of Bleeding History of Bleeding Right Heart Catheterization Right Heart Catheterization GPIIb-IIIa antagonists GPIIb-IIIa antagonists

P-value RR (95% CI) Risk ratio ± 95% CI Predictors of Major Bleeding Age >75 (vs ) Anemia CrCl <60mL/min Diabetes Female gender High-risk (ST / biomarkers) Hypertension Heparin(s) + GPI (vs. Bivalirudin) 1.56 ( ) ( ) < ( ) < ( ) ( ) < ( ) ( ) ( ) < Manoukian SV, Voeltz MD, Feit F et al. TCT Results: The ACUITY Trial PCI Population MA…

REPLACE-2 Multivariate Predictors of Major Bleeding RISK FACTORS Odds Ratio 95% CI p-value Baseline risk factors Age > to Gender (M vs. F) to Prior Angina to Creatinine clearance* to Anemia to Peri-procedural risk factors Treatment Group (BIV vs. H+GPI) to Provisional GPI received to Procedure Duration >1h to Time to Sheath Removal >6h to ICU stay (days) to < IABP to < Feit F et al.

Il sanguinamento influenza la prognosi del paziente? Bleeding in ACS Domanda:

Moscucci M et al. Eur Heart J 2003;24: P<0.001 Overall Unstable NSTEMI STEMI ACS Angina ACS Angina Patients (%) Major Bleeding Predicts Mortality in ACS 24,045 ACS patients in the GRACE registry, in-hospital death

log rank p-value for all four categories < log-rank p-value for no bleeding vs. mild bleeding = 0.02 log-rank p-value for mild vs. moderate bleeding < log-rank p-value for moderate vs. severe <0.001 Bleeding & Outcomes Rao SV, et al. Am J Cardiol Nov 1;96(9): Epub 2005 Sep 12 Kaplan Meier Curves for 30-Day Death, Stratified by Bleed Severity N=26,452 ACS patients from GUSTO IIb, PARAGON A, PARAGON B, & PURSUIT

Major Bleeding, Ischemic Endpoints, and Mortality P< for all Manoukian SV, Voeltz MD, Feit F et al. TCT Results: The ACUITY Trial PCI Population (N=7,789)

Major Bleeding and Myocardial Infarction P< for all Manoukian SV, Voeltz MD, Feit F et al. TCT Results: The ACUITY Trial PCI Population (N=7,789)

Major and Minor Bleeding in PCI Bleeding Increases Mortality and Events Kinnaird TD et al. AM J Cardiol 2003;92: ,974 patients undergoing PCI, Washington Hospital Center, In-Hospital Clinical Events Major(n=588)Minor(n=1,394)None(n=8,992) Death 7.5%* 7.5%* 1.8%*0.6% Q-wave myocardial infarction 1.2%* 0.7% 0.7% 0.2% Non-Q-wave myocardial infarction 30.7%* 30.7%* 16.8%*11.8% Repeat lesion angioplasty 1.9%* § 0.8% 0.8% 0.3% Major adverse cardiac event 6.6%* 6.6%* 2.2%*0.6% Bleeding Complication * p<0.001 versus none p<0.001 versus minor p<0.01 versus none § p<0.05 versus minor

Come valutare lentità del sanguinamento? Bleeding in ACS Domanda:

Bleeding Incidence in ACS Clinical Trials Rao SV, et al. J Am Coll Cardiol Feb 21;47(4): Epub 2006 Jan 26

Bleeding Definitions TIMI Definition TIMI Definition l Major ICH ICH Associated with Hgb decrease 5 g/dl or HCT decrease 15% Associated with Hgb decrease 5 g/dl or HCT decrease 15% l Minor Observed blood loss associated with Hgb decrease 3 g/dl or HCT decrease 10% Observed blood loss associated with Hgb decrease 3 g/dl or HCT decrease 10% No identifiable source but Hgb decrease 4 g/dl or HCT decrease 12% No identifiable source but Hgb decrease 4 g/dl or HCT decrease 12% l Minimal Overt hemorrhage with Hgb drop < 3 g/dl or HCT drop < 9% Overt hemorrhage with Hgb drop < 3 g/dl or HCT drop < 9% Chesebro JH. Circulation Jul;76(1):

N Engl J Med Nov 25;329(22): Erratum in: N Engl J Med 1994 Feb 17;330(7):516 Bleeding Definitions GUSTO Definition GUSTO Definition l Severe or life threatening ICH or hemodynamic compromise requiring treatment ICH or hemodynamic compromise requiring treatment l Moderate Requiring transfusion Requiring transfusion l Mild Not meeting criteria for Severe or Moderate Not meeting criteria for Severe or Moderate

Bleeding Scales Among NSTE ACS Patients Bleeding Scales Among NSTE ACS Patients Rao SV, et al. J Am Coll Cardiol Feb 21;47(4): Epub 2006 Jan 26 TIMI and GUSTO – Adjusted Hazard of 30 d Death/MI N=15,858

La trasfusione ha un impatto sulla prognosi? La trasfusione è in grado di correggere leffetto negativo del sanguinamento? La trasfusione ha un impatto sulla prognosi? La trasfusione è in grado di correggere leffetto negativo del sanguinamento? Bleeding in ACS Domanda:

30-Day Survival By Transfusion Group Rao SV, et. al., JAMA 2004;292:1555–1562 Transfusion in ACS N=24,111N=24,111 METANALYSIS OF the GUSTOIIb,PURSUIT,and PARAGON b trials

*Transfusion as a time-dependent covariate PRBC Transfusion Among NSTE ACS Patients: Cox Model for 30-day Death PRBC Transfusion Among NSTE ACS Patients: Cox Model for 30-day Death Rao SV, et. al., JAMA 2004;292:1555–1562 N=24,111N=24,111 METANALYSIS OF the GUSTOIIb,PURSUIT,and PARAGON b trials

Adjusted Risk of In-Hospital Outcomes By Transfusion Status* Adjusted Risk of In-Hospital Outcomes By Transfusion Status* *Non-CABG patients only Yang X, J Am Coll Cardiol 2005;46:1490–5. N=74,271 ACS patients from CRUSADE

Transfusion, Ischemic Endpoints, and Mortality P< for all Manoukian SV, Voeltz MD, Feit F et al. TCT Results: The ACUITY Trial (N=13,819)

Increased 1-year mortality in transfused patients Adjusted Odds Ratio 4.26 (2.25–8.08) Transfusion Post PCI: REPLACE 2 One Year Mortality P< Manoukian SV, Voeltz MD, Attubato MJ, Bittl JA, Feit F, Lincoff AM. CRT Abstract.

1.With time and storage, red blood cells undergo a reduction in their adenosine triphosphate and 2,3 diphosphoglycerate stores, which may decrease oxygen unloading at the tissue level 2.Storage may also affect the ability of red blood cells to deform and maneuver in capillaries, leading to diminished oxygen delivery to the myocardium via the large coronary arteries.

storage lesions: aumento fragilità di membrana (ridotta deformabilità) alterata capacità di trasporto dellossigeno pH ridotto riduzione del n° cellule vitali/unità aumento delle citochine pro-infiammatorie (leucociti contaminanti) alterata biologia dellNO nel sangue conservato bassi livelli di 2,3 difosfoglicerati -> aumentata affinità dellO 2 per lHb

EMOTRASFUSIONI NEGLI ANZIANI CON IMA Wu W-C NEJM 2001;345: pz Medicare con IMA > 65 aa ematocrito (%) OR (95% CI) di morte < 30 gg con aggiustamento per i fattori clinici, i farmaci e i predittori di trasfusioni 5.0 – ( ) 24.1 – (0.34 – 0.69) 27.1 – (0.47 – 0.76) 30.1 – (0.53 – 0.89) 33.1 – (0.89 – 1.44) 36.1 – (1.05 – 1.80) 39.1 – (1.18 – 1.81)

High Risk Patient Subgroups

Bleeding RisksTransfusions by Age Alexander KA, JAMA 2005;294:3108–16.

6,002 patients in REPLACE patients (13.4%) classified as elderly, >75 years of age p<0.0001p= REPLACE-2: Elderly Patients Have Increased Major Bleeding and Transfusions = Not Elderly, <75 = Elderly, >75 Voeltz MD, Lincoff AM, Feit F, Manoukian SV. Circulation 2005;112(17):II-613. Abstract.

p< p= ,002 patients in REPLACE patients (13.4%) classified as elderly, >75 years of age. 806 patients (13.4%) classified as elderly, >75 years of age. Elderly Patients in REPLACE-2: Increased 30-Day Mortality With Major Bleeding and Transfusions Voeltz MD, Lincoff AM, Feit F, Manoukian SV. Circulation 2005;112(17):II-613. Abstract.

Excessive Dosing of Anticoagulants by Age Alexander KA, JAMA 2005;294:3108– LMW HeparinUF HeparinGP Iib/IIIa % Excsessive dose <65 yrs65-75 yrs>75 yrs

Excess Dosing of Gp IIb/IIIa and Bleeding in Women OverallOverall WomenWomen MenMen 1.46 (1.22, 1.73) 1.72 (1.30, 2.28) 1.27 (0.97, 1.66) Excess Dosing More Likely to Bleed Alexander KP, et. al. Circulation 2006 N=32,601 patients from CRUSADE

Bleeding is Increased in Patients With Impaired Renal Function Undergoing PCI 60 ml/min N= ml/min N=4824 < 60 ml/min N=886 p value 30-d Death 5 (0.1%) 14 (1.6%) < < d Myocardial infarction 305 (6.3%) 75 (8.5%) d urgent revascularization 61 (1.3%) 10 (1.1%) Triple ischemic endpoint 338 (7.0%) 84 (9.5%) In-hospital protocol major bleeding 123 (2.5%) 54 (6.1%) < < TIMI major + minor bleeding 114 (2.4%) 46 (5.2%) < < Creatinine Clearance Chew DP et al. Am J Cardiol 2005;95:581–585.

enoxaparinCrCl < 30controindicata o dose fondaparinuxCrCl < 30 controindicata – tuttavia emorragie vs enox bivalirudin CrCl < 30 emodialisi dose 1 mg/kg/h dose 0.25 mg/kg/h tirofibanCrCl < 30 dose 50 % eptifibatide CrCl < 50 < 30 dose 50 % controindicato abciximab valutazione attenta del rischio emorragico farmaci antitrombotici e antiaggreganti, insufficienza renale e rischio emorragico

Major Bleeding is Increased in Anemic Patients Undergoing PCI 6,010 patients in REPLACE-2. 1,362 patients (22.7%) classified as anemic based upon WHO definition. Major bleeding = 3.2% Major Bleeding 2.8% 4.9% P= Protocol definition: >3g/dL drop in HgB, intracranial, retroperitoneal, 2U transfusion Voeltz MD, Attubato MJ, Feit F, Lincoff AM, Manoukian SV. J Am Coll Cardiol 2005;45(3)[Suppl A]: A. Abstract.

NSTE-ACS Mortality Stratified by Hemoglobin Sabatine MS. Circulation 2005 Unadjusted Hb (g/dL)nOR(95% Cl)OR(95% Cl)P value > (1.03–2.10)1.45(0.94–2.23) – (0.97–1.51)1.27(0.98–1.65) – reference1.0 reference 14– (0.89–1.22)1.11(0.93–1.33) – (0.88–1.19)1.04(0.86–1.24) – (0.92–1.28)1.07(0.88–1.30) – (0.97–1.47)1.04(0.81–1.34) – (1.05–1.89)1.29(0.92–1.82) – (1.88–3.18)2.69(2.01–3.60)< – (1.88–3.18)2.69(2.01–3.60)< – (1.69–2.96)2.45(1.80–3.33)<0.001 < (2.76–5.70)3.49(2.35–5.20)<0.001 Abbreviations: CI, confidence interval; Hb, hemoglobin; OR, odds ration. Adapted with permission. Abbreviations: CI, confidence interval; Hb, hemoglobin; OR, odds ration. Adapted with permission. Unadjusted and adjusted odds ratios for cardiovascular mortality in patients with non-ST elevation acute coronary syndromes at 30 days stratefied by hemoglobin Adjusted for baseline characteristics

Thrombocytopenia Induced by Abciximab Abciximab is a widely used chimeric (human–mouse) Fab fragment that is specific for β3 integrin (glycoprotein IIIa); It blocks platelet–fibrinogen interaction; Abciximab itself does not cause thrombocytopenia because it lacks the Fc domain required for recognition of antibody-coated platelets by phagocytes; However, in about 1% of patients given abciximab for the first time, and in more than 10% of those treated a second time, acute thrombocytopenia develops within a few hours of starting an infusion; In some patients the onset of thrombocytopenia is delayed until 5 to 8 days after the initial 24- to 48-hour period of exposure to the drug; Abciximab- induced thrombocytopenia is often mild, but fatalities have been recorded.

indicazioni alla trasfusione di piastrine 4Shander A Pharmacotherapy 2007;27(9 Pt 2):57S piastrinopenia severa (< 50 x 10 3 /mmc) in caso di sanguinamento attivo prevenzione del sanguinamento in caso di piastrinopenia molto severa (< 5-10 x 10 3 /mmc) piastrinopenia severa (< 50 x 10 3 /mmc) prima di una procedura invasiva prevenzione del sanguinamento spontaneo in pazienti con piastrinopenia severa (<10-50 x 10 3 /mmc), in caso di sepsi, uso di antibiotici, altre anoma- lie della coagulazione nei disordini della funzione piastrinica (uremia, tromboastenia, farmaci antipiastrinici), in caso di sanguinamento attivo.

E causata da anticorpi diretti contro il complesso PF4 piastrinico ed eparina Compare dopo circa 5-10 giorni dall inizio della terapia in pazienti non precedentemente esposti (oltre 100 gg), in poche ore se vi è stato un recente trattamento Può essere molto severa anche valori inferiori a per mmc, con lenta risalita (4-14 gg), dopo la sospensione del farmaco. E raramente associata a fenomeni emorragici, invece predominano le complicanze trombotiche (25-50% dei pz) con un rischio di trombosi 30 volte maggiore che nella popolazione di controllo E 10 volte più frequente nei pz trattati con UHF vs LMWH Se sospetto clinico ricerca di anticorpi per il complesso PF4-eparina, eventuale test funzionali di aggregazione piastrinica -> sospensione della terapia eparinica -> anticoagulazione

1.Associazione temporale 2.Nova insorgenza di trombosi 3.Risalita dopo sospensione

dosaggio ASA (+ clopidogrel) ed emorragie - CURE - 4Peters RJG Circulation 2003;108:1682.

THANK YOU FOR YOUR ATTENTION